Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05939791
Other study ID # 22-0047
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date December 31, 2023

Study information

Verified date January 2024
Source Comenius University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to to compare the structure of the intestinal microbiome between children shortly after treatment for acute lymphoblastic leukemia (1-3 years after cancer treatment) and healthy controls. And then to provoke a positive shift of bacterial diversity by physical activity and probiotics in cured pediatric oncology patients with persistent gut microbiome disruptions. The main question[s] it aims to answer are: - Are differences in bacterial richness between healthy controls and pediatric oncology patients ≥12 months after cancer treatment apparent? - Has the combination of physical exercise and probiotics had a positive influence on the structure of the gut microbiome in childhood cancer survivors in remission? Two times per week of physical activity and daily dairy consumption with probiotics will be required of participants for eight weeks.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: - children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years Exclusion Criteria: - acute respiratory infection during intervention - more than 20% skipped exercise training sessions

Study Design


Related Conditions & MeSH terms

  • Acute Lymphoblastic Leukemia, Pediatric
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Other:
Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518
The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
Physical exercise
The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.

Locations

Country Name City State
Slovakia Department of Pediatric Hematology National Institute of Children's Diseases Bratislava Bratislava

Sponsors (1)

Lead Sponsor Collaborator
Comenius University

Country where clinical trial is conducted

Slovakia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The shift of gut microbiome by physical exercise and consumption of dairy probiotics. 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Enrolling by invitation NCT05622682 - Vaccine Immune Recovery After Leukemia
Not yet recruiting NCT05029531 - Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) Phase 3
Not yet recruiting NCT06107478 - Parental Perception of Their Child's Emotional Quality of Life in Paediatric Oncology Before and After "Magic Massages"
Recruiting NCT04049383 - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL Phase 1
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Completed NCT05973032 - MRD Detection by NGS in Pediatric B-ALL
Completed NCT05032716 - EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA N/A
Not yet recruiting NCT05809284 - Determining the Mechanisms of Loss of CAR T Cell Persistence
Recruiting NCT03035344 - Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) N/A
Terminated NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia Phase 1/Phase 2
Recruiting NCT04325841 - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Phase 2
Active, not recruiting NCT03020030 - Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Phase 3
Not yet recruiting NCT06257394 - Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea Phase 2
Active, not recruiting NCT03157323 - Low GI Diet in Children and Adolescents With ALL N/A
Recruiting NCT04996160 - Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) Phase 1
Recruiting NCT03643276 - Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Phase 3
Recruiting NCT06074666 - Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 N/A
Active, not recruiting NCT04088864 - CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Phase 1
Completed NCT04770922 - Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia